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Abstract
As HIV-infected adults on successful antiretroviral therapy (ART) are expected to have
close to normal lifespans, they will increasingly develop age-related comorbidities. The
objective of this cross-sectional study was to compare in the French Dat’AIDS cohort, the
HIV geriatric population, aged 75 years and over, to the elderly one, aged from 50 to 74
years. As of Dec 2015, 16,436 subjects (43.8% of the French Dat’AIDS cohort) were aged
from 50 to 74 (elderly group) and 572 subjects (1.5%) were aged 75 and over (geriatric
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group). Durations of HIV infection and of ART were slightly but significantly different, median
at 19 and 18 years, and 15 and 16 years in the elderly and geriatric group, respectively. The
geriatric group was more frequently at CDC stage C and had a lower nadir CD4. This group
had been more exposed to first generation protease inhibitors and thymidine analogues.
Despite similar virologic suppression, type of ART at the last visit significantly differed
between the 2 groups: triple ART in 74% versus 68.2%, ART 4 drugs in 4.7% versus
2.7%; dual therapy in 11.6% versus 16.4% in the elderly group and the geriatric group,
respectively. In the geriatric group all co-morbidities were significantly more frequent, except
dyslipidemia, 4.3% of the elderly group had4 co-morbidities versus18.4% in the geriatric
group. Despite more co-morbidities and more advanced HIV infection the geriatric popula-
tion achieve similar high rate of virologic suppression than the elderly population. A multidis-
ciplinary approach should be developed to face the incoming challenge of aging HIV
population.
Introduction
As a benefit of long term suppressive antiretroviral therapy with improved tolerability, the
number of aging HIV infected individuals is increasing with about half of them above 50 years
of age or over in high-income countries [1, 2]. Both life expectancy and mortality rates
improved over time linked with coverage improvement, quality and tolerability of ART regi-
mens and HIV care[3, 4]. A 20-year-old HIV-positive adult on ART in the U.S. or Canada is
expected to live into his early 70‘s, a life expectancy approaching that of the general population.
However, large differences in life expectancy persist between certain sub-groups of patients
according to sex, race, HIV transmission risk group, lifestyle and CD4 cell counts at ART initi-
ation[3, 5, 6]. It is well-established that multimorbidity increases with age, moreover comor-
bidities, including cardiovascular diseases, diabetes, cancer, cognitive dysfunction, depression
and osteopenia are more frequent in the HIV population[7–11]. Many age-related illnesses
can be driven by HIV itself, and drug toxicities may play a role in specific organ systems and
interact with medical conditions typically associated with advanced age[2, 12]. Due to the
increased risk of age-related co-morbidities among HIV-positive adults, it is possible that life
expectancy may plateau or decrease in the future. However, the concept of premature aging of
HIV-infected persons appears to be controversial, particularly when considering the investiga-
tion of the effects of age on non–AIDS-defining malignancies[13].
Even if aging HIV cohorts included subjects aged 50 years and older, so far few of them
have focused on geriatric population of HIV-infected patients aged 75 and over. It could be
anticipated that the geriatric HIV population will have more co-morbidities and co-medica-
tions, much longer HIV infection, then more complex and/or less standard antiretroviral regi-
mens, therefore a higher risk of not being virologically suppressed. The objective of this study
was to assess to which extent the HIV geriatric population aged 75 and older differed from the
HIV elderly population in terms of demographic and immuno-virological characteristics,
ART history and current ART, and comorbidities.
Material and methods
Dat’AIDS cohort is a French multicentric prospective cohort involving 19 HIV reference cen-
tres in France (Clinicaltrials.gov ref NCT02898987). These reference centres maintain
Geriatric HIV population, antiretroviral exposure and comorbidities
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prospective databases of all HIV infected patients seeking care in the centres and providing
written consent. The data collection has been approved by the French national commission on
informatics and liberty (CNIL). The database is implemented via an electronic medical[14].
Dat’AIDS cohort collects sociodemographic and clinical data, medical and ARV history,
immunological and virological status at regular 3- to 6- month intervals during routine clinical
assessment.
For the purpose of the study we selected all HIV patients aged 50 year-old and over at the
last visit, with at least one visit since 2004 and still on follow-up at the censoring date (Dec 31st
2015). Patients were classified as “elderly” if they were aged between 50 and 74 and “geriatric”
if they were aged 75 or older at the latest visit. Medical history collected data on past or current
diabetes (insulin-dependent or non insulin-dependent diabetes), hypertension (confirmed
blood pressure above 140/90 mm Hg or hypertension treatment), dyslipidaemia (hypercholes-
terolemia and/or hypertriglyceridemia or treatment with lipid lowering agent), history of car-
diovascular disease (ischemic cardiovascular disease or stroke), depression, and cancer. Renal
insufficiency was defined by a confirmed estimated glomerular filtration rate below 60 ml/
min/1.73 m2, as calculated using the Modification of Diet in Renal Disease (MDRD) formula.
Continuous variables were described by their medians and interquartile ranges (IQR) and
compared between groups using a Mann-Whitney test. Categorical variables were described
by proportions and compared by chi-square tests. R software version 3.0.2 was used for the
analyses.
Results
Among the 37,511 HIV infected adult patients included in the Dat’AIDS cohort with at least
one visit since 2004 and still on follow-up at the 31 December 2015, 17 008 (45.3%) were older
than 50 years (S1 Dataset). Among them 16,436 subjects were aged between 50 and 75 years
and classified in the elderly group and 572 subjects were aged 75 years or older and classified
in the geriatric group. The geriatric group represented 1.5% of the whole population. Socio-
demographics and clinical characteristics of the elderly and geriatric groups are presented in
Table 1. At the last visit, there was no difference in the proportion of HIV-1 infected subjects
on ART, 97.3% and 97.2% in the geriatric and the elderly group, respectively, with a duration
of known HIV infection slightly shorter in the geriatric group than in the elderly group (18.0
vs 19.0 years, p = 0.029) and a median duration of ART significantly longer in the geriatric
group than in the elderly group, (16.0 vs 15.0 years, p = 0.003).
At last visit, elderly patients were more frequently receiving a standard triple ART com-
pared to of geriatric patients (74% and 68.2% respectively, p = 0.003), while proportion of
patients receiving 4 or more ARVs and a dual therapy were 4.7% and 11.6% for the elderly
group and2.7% and 16.5% for the geriatric grou, respectively (p = 0.042 and p<0.001). ART
regimens at the last visit for elderly and geriatric HIV-1 infected patients are detailed in
Table 2. Plasma HIV RNA was below 50 copies/mL in 90.6% and 90.9% of the subjects on
ART in the elderly and geriatric group, respectively (p = 0.932).
The elderly group had been less frequently exposed than the geriatric group to first-genera-
tion protease inhibitors and nucleoside reverse transcriptase inhibitors, 51.7% versus 59.0%
(p<0.001) and 71.0% vs 79.9% (p<0.001), respectively. Exposure to non-nucleoside reverse
transcriptase inhibitors and integrase inhibitors was similar between both groups (Table 3).
Co-morbidities were significantly more frequent in the geriatric group, except for dyslipide-
mia (Table 4). The most frequent comorbidities in the geriatric group were dyslipidemia
(60.8%), hypertension (43.5%), chronic renal disease (29.4%) and cardiovascular disease
(23.4%). In the geriatric group, 32.2% of the subjects had no more than one comorbidity,
Geriatric HIV population, antiretroviral exposure and comorbidities
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Table 1. Socio-demographic, clinical and immune-virological characteristics of the Elderly and Geriatric populations.
Elderly 50–74 Geriatric 75 P. value
n = 16 436 n = 572
Age, median [IQR] 56 [52–61] 78 [76–81] < 0.001
Male, n (%) 12,300 (74.8) 416 (72.7) 0.275
HBV and/or HCV Hepatitis coinfection, n (%) 4,118 (25.1) 53 (9.3) < 0.001
HIV-2 infection, n (%) 205 (1.2) 5 (0.9) 0.547
HIV transmission, n (%) < 0.001
heterosexual 6,871 (44.7) 281 (55.4)
MSM 6,057 (39.4) 194 (38.3)
others 2,431 (15.8) 32 (6.3)
Country of birth, n (%) < 0.001
France 6,800 (64.5) 238 (68.0)
African countries 1,811 (17.2) 32 (9.1)
Others 2,308 (18.3) 80 (22.9)
Age at HIV diagnosis, median [IQR] 39 [31–48] 61 [56–67] <0.001
<50 year-old, n (%) 13,318 (81.3) 40 (7.0)
50–75 year-old, n (%) 3,063 (18.7) 485 (85.1)
75 year-old, n (%) 0 (0.0) 45 (7.9)
Time since HIV diagnosis, year, med. [IQR] 19 [11–25] 18 [13–23] 0.029
CDC stage C, n (%) 4,713 (28.8) 192 (33.6) 0.015
CD4/mm3 at diagnosis, median [IQR] 300 [122–495] 246 [113–430] 0.039
Nadir CD4 /mm3, median [IQR] 183 [70–297] 159 [71–268] <0.001
BMI, n (%) < 0.001
underweight1 688 (4.3) 119 (21.6)
normal weight2 9,596 (60.6) 390 (70.8)
overweight3 4,142 (26.2) 30 (5.4)
obesity4 1,402 (8.9) 12 (2.2)
25(OH)Vitamin D, ng/mL, median [IQR] 31 [21–45] 30 [21–45] 0.716
Serology CMV positive, n (%) 10,443 (87.2) 373 (93.0) < 0.001
Current smoker, n (%) 4,874 (38.7) 31 (7.5) < 0.001
Alcohol abuse, n (%) 2,980 (26.1) 83 (21.5) 0.049
IVDU current/past, n (%) 4,901 (38.6) 96 (23.0) < 0.001
At last visit
CD4 /mm3, median [IQR] 504 [324–720] 456 [304–634] < 0.001
CD4/CD8 ratio, median [IQR] 0.6 [0.4–1.0] 0.6 [0.4–0.9] 0.137
CD4500/mm3 and CD4/CD81, n (%) 2,452 (19.8) 74 (17.1) 0.178
HIV RNA <50 c/mL, n(%) 10,893 (89.8) 384 (89.9) 0.969
HIV RNA <50 c/mL on ART5, n(%) 10,739 (90.6) 378 (90.9) 0.932
BMI (Body Mass Index)
 Hepatitis B virus and/or Hepatitis C virus co-infection
1 <18 in Elderly, <21 in Geriatric
2 18–25 in Elderly, 21–30 in Geriatric
3 25–30 in Elderly, 30–35 in Geriatric
4 >30 in Elderly, >35 in Geriatric
5HIV-1 only
 More than 2 glasses of alcohol per day
https://doi.org/10.1371/journal.pone.0203895.t001
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49.5% had 2 or 3 comorbidities and 18.4% had 4 comorbidities or more, compared to 60.1%,
34.7% and 5.3%, respectively in the elderly group.
Discussion
This study describes an aging HIV-infected population and because of the large population
size we were able to compare an elderly population aged 50 to 74 years to a geriatric population
aged 75 and over. To our knowledge our study is the first one to describe HIV and ART his-
tory, as well as comorbidities in a geriatric HIV population and shows that the high rate of
virologic suppression is similar within the 2 groups despite more frequent comorbidities, a
longer exposure to first generation protease inhibitors and thymidine analogs and more fre-
quent non classical antiretroviral regimen in the geriatric group. Interestingly, the geriatric
group had a significantly shorter duration of HIV infection than the elderly group, and had a
significantly longer duration of antiretroviral therapy than the elderly population. However,
these differences were only around 1 year, while difference in median age of the 2 groups was
22 years, suggesting that the geriatric group either acquired HIV infection at an already
advanced age (93% of the geriatric subjects were diagnosed after 50 years old and among them
7.9% after 75 years old), or was diagnosed late after many years of latent chronic HIV infection
(median age at HIV diagnosis of 61 years). Indeed, the geriatric group had a significantly
lower nadir CD4 cell count and a higher prevalence of CDC stage C and a median age at HIV
diagnosis of 61 years. Of note, and in contrast with the elderly group, geriatric patients had
Table 2. Current ART regimens in the elderly and geriatric groups (restricted to HIV-1 infected subjects).
Variable Elderly (50–74) Geriatric (75) P. value
On ART, n (%) 15,795 (96.1) 551 (96.3) 0.914
Duration on ART, year, median [IQR] 15 [8–19] 16 [10–19] 0.003
ART regimen
Triple therapy, n (%) 11,692 (74.0) 376 (68.2) 0.003
2 NRTIs + 1 INSTI, n (%) 3,590 (22.7) 116 (21.1) 0.383
2 NRTIs + 1 PI, n (%) 258 (1.6) 16 (2.9) 0.034
2 NRTIs + 1 bPI, n (%) 2,845 (18.0) 77 (14.0) 0.018
2 NRTIs + 1 NNRTI, n (%) 4,894 (31.0) 156 (28.3) 0.198
3 NRTIs, n (%) 105 (0.7) 11 (2.0) < .001
Monotherapy, n (%) 402 (2.5) 18 (3.3) 0.360
Monotherapy with bPI, n (%) 368 (2.3) 17 (3.1) 0.314
Other, n (%) 34 (0.2) 1 (0.2) 0.999
Dual therapy, n (%) 1,831 (11.6) 91 (16.5) < .001
bPI + NNRTI, n (%) 220 (1.4) 6 (1.1) 0.678
bPI + INSTI, n (%) 376 (2.4) 14 (2.5) 0.920
bPI + LAM, n (%) 63 (0.4) 4 (0.7) 0.400
bPI + other, n (%) 182 (1.2) 6 (1.1) 0.999
INSTI + NNRTI, n (%) 613 (3.9) 31 (5.6) 0.050
2 NRTIs, n (%) 59 (0.4) 5 (0.9) 0.104
Other with no bPI, n (%) 318 (2.0) 25 (4.5) < .001
4 drugs and more, n (%) 737 (4.7) 15 (2.7) 0.042
ART: antiretroviral therapy, PI: protease inhibitor, bPI: boosted protease inhibitor, NRTI: nucleoside/nucleotide reverse transcriptase inhibitor, NNRTI: non-nucleoside
reverse transcriptase inhibitor, INSTI: integrase inhibitor, LAM: lamivudine
 Continuous variables were compared using a Mann-Whitney test. Categorical variables were compared by χ2 tests.
https://doi.org/10.1371/journal.pone.0203895.t002
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acquired HIV mainly through heterosexual contact, which could contribute to a lower percep-
tion of the risk of HIV infection and to increased delay for HIV testing. Studies on missed
Table 3. ART exposure in the elderly and geriatric groups (restricted to HIV-1 infected subjects on ART).
Exposure to ARV and duration (months)
in exposed patients
Elderly (50–74) Geriatric (75) P. value
n = 15,795 n = 551
N(%) Median [IQR] N(%) Median [IQR]
PI 13,205 (83.6) 94 [41–154] 461 (83.7) 94 [39–150] 0.999
First generation PI 1 8,170 (51.7) 49 [26–89] 325 (59) 45 [24–78] < .001
LPV/RTV 5,721 (36.2) 38 [14–76] 202 (36.7) 33 [9–73] 0.868
DRV/RTV 5,690 (36) 41 [17–68] 164 (29.8) 44 [20–68] 0.003
ATV/RTV 5,499 (34.8) 55 [22–92] 183 (33.2] 67 [27–100] 0.465
NRTI 15,719 (99.5) 159 [93–218] 551 (100) 175 [110–226] 0.189
First generation NRTI2 11,213 (71) 97 [58–136] 440 (79.9) 107 [63–153] < .001
TDF 12,849 (81.3) 73 [36–107] 387 (70.2) 69 [25–97] < .001
ABC 9,076 (57.5) 58 [18–109] 370 (67.2) 66 [21–122] < .001
NNRTI 11,897 (75.3) 62 [23–120] 423 (76.8) 74 [25–144] 0.468
Nevirapine 5,332 (33.8) 40 [9–110] 222 (40.3) 54 [11–139] 0.002
Efavirenz 6,810 (43.1) 41 [11–94] 226 (41) 43 [10–110] 0.350
Rilpivirine 2,570 (16.3) 20 [9–31] 75 (13.6) 11 [6–21] 0.108
Etravirine 2,521 (16) 39 [16–67] 72 (13.1) 51 [32–78] 0.077
INSTI3 6,999 (44.3) 28 [10–67] 253 (45.9) 36 [12–66] 0.483
Enfuvirtide 776 (4.9) 13 [5–28] 24 (4.4) 9 [6–15] 0.620
PI: protease inhibitor, LPV: lopinavir, DRV: darunavir, ATV: atazanavir, RTV: ritonavir, NRTI: nucleoside/nucleotide reverse transcriptase inhibitor, TDF: tenofovir
DF, ABC: abacavir, ZDV: zidovudine, NNRTI: non-nucleoside reverse transcriptase inhibitor, INSTI: integrase inhibitor
1 RTV full dose, ampre´navir, fosamprenavir, indinavir, nelfinavir, saquinavir, tipranavir
2zidovudine, didanosine, stavudine, zalcitabine
3 raltegravir, elvitegravir/cobicistat, dolutegravir
 Exposures were compared by χ2 tests
https://doi.org/10.1371/journal.pone.0203895.t003
Table 4. Co-morbidities in the Elderly and Geriatric group.
Co-morbidity Elderly (50–74) Geriatric (75) P.value
n = 16,436
N(%)
n = 572
N(%)
Diabetes 1490 (9.1) 126 (22) < .001
Hypertension 3452 (21) 249 (43.5) < .001
Chronic renal disease 738 (4.5) 168 (29.4) < .001
Dyslipidemia 9584 (58.3) 348 (60.8) 0.245
Cardiovascular disease 1775 (10.8) 134 (23.4) < .001
Osteoporosis 1046 (6.4) 72 (12.6) < .001
Depression 2933 (17.8) 80 (14) 0.020
Cancer 2026 (12.3) 131 (22.9) < .001
Number of comorbidities
0–1 9870 (60.1) 184 (32.2) < .001
2–3 5701 (34.7) 283 (49.5)
 4 865 (5.3) 105 (18.4)
 Co-morbidities were compared by χ2 tests
https://doi.org/10.1371/journal.pone.0203895.t004
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opportunities for HIV diagnosis have identified old age and being heterosexual has significant
risk factors for being diagnosed late [15, 16]. Although the geriatric population had been more
frequently exposed to first-generation ARVs, including protease inhibitors and thymidine ana-
logue nucleoside reverse transcriptase inhibitors, they were less likely to receive complex regi-
mens consisting of 4 ARVs or more and more likely to receive a dual therapy. This suggests
that with newer ARVs, the need for complex antiretroviral regimens consisting of multiple
drugs because of cumulative or cross-resistance is decreasing. On the other hand, because of a
higher prevalence of co-morbidities, a higher number of co-medications, or an age-related
chronic renal impairment, adaptation of treatment to avoid cumulative toxicities or drug-
drug-interactions is probably more frequently needed in geriatric patients, which could
explain the more frequent use of dual therapy in this population. Use of nucleosidic- and PI-
sparing regimens to avoid the cumulative toxicity of antiretroviral therapy represents a major
issue, particularly in aging subjects highly ART experienced, confronted with lipodystrophy,
renal, cardio-vascular and other co-morbidities. Dual therapy has been shown to be a possible
switch option in virologically suppressed patients, as long as certain conditions are fulfilled
[17]. Some of these dual therapies have been evaluated among them combination of an inte-
grase inhibitor plus a non nucleosidic reverse transcriptase inhibitor, lamivudine or maraviroc
with a benefit on lipid profile and bone mineral density[18–20]. The combination of one inte-
grase inhibitor plus one non nucleosidic reverse transcriptase inhibitor was the dual therapy
most frequently prescribed in the geriatric group. Recent data of the ANRS163-ETRAL study
showed the robust and potent activity with an excellent safety profile of the dual therapy ralte-
gravir plus etravirine in subjects over 45 years virologically suppressed and with a long history
of antiretroviral therapy and frequent lipodystrophy[21]. The dual therapy in maintenance of
dolutegravir plus either rilpivirine or lamivudine have also shown reassuring results both on
efficacy and renal tolerability, with the advantage of a simple once-daily regimen[22] [18].
With the development of these new promising PI-sparing and/or NRTI-sparing switch dual
therapy, future studies need to address their specific benefit in HIV geriatric patients. Interest-
ingly, not only older age but also a high number of comorbidities was driving the choice for a
mono/dual therapy. These data suggest that physicians are more and more concerned about
prevention of comorbidities and long-term toxicities.
In the general population, co-morbidities are increasing with age and are not linear but
rather significantly accelerate at older age. Our result is consistent with the study of Guaraldi
at al. where 14% of patients aged 60 year-old and over had 4 comorbidities or more[23]. Some
studies have shown a higher and earlier frequency of these comorbidities in the HIV popula-
tion compared with the general population[5, 24]. Some of these comorbidities may be
induced or worsened by ART. In our study geriatric patients had been more often exposed to
first generation antiretrovirals including oldest PI favouring metabolic syndrome, and increas-
ing cardiovascular risk and thymidine analogs responsible for lipoatrophy and mitochondrial
toxicity. In the Dutch AgeHIV cohort with a median age of 52.4 years, prevalence of hyperten-
sion is high (46.2%) and the authors show that changes in body composition, involving both
abdominal obesity and stavudine-induced peripheral lipoatrophy, might contribute to the
higher prevalence of hypertension in HIV-1-infected patients [25]. Neurocognitive dysfunc-
tion, obstructive pulmonary disease, and osteoporosis, have also been linked to low nadir CD4
+ T-cell counts[26].
In the centers from which the data were drawn, the proportion of individuals aged 50 years
and over on ART and with HIV RNA < 50 c/mL on treatment is very similar to the global
population (96% and 89.9% vs 94.3% and 87.4%, respectively (n = 35890, personal data). On
ART, despite a high rate of virological success above 90% and a long duration on ART above
15 years, quality of immune reconstitution (considered as optimal if CD4 count is above 500/
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mm3 and CD4:CD8 ratio above 1) was poor in this aging population both in the elderly and
the geriatric groups with only 19.8% and 17.1% of the subjects reaching both more than 500
CD4 cell/mm3 and a CD4:CD8 ratio above 1, respectively, as it was pointed out in some stud-
ies [27]. Many similarities on immunological alterations have been observed between middle-
aged HIV-infected individuals and non-HIV geriatric subjects[28]. It is of importance to point
out that very few elderly patients have been included in studies assessing HIV aging and the
relative impact of HIV infection and other parameters on inflammatory and immune disor-
ders has not yet been fully studied in this population[29]. Hentzien et al. studied the impact of
age related morbidities on on five-year overall mortality in an aging population aged 60 and
over. They showed that age-related comorbidities—particularly cardiovascular diseases and
chronic renal disease—were the main prognostic factors for mortality, at the same weight as
CD4 cell count[30]. In this context of highly experienced elderly patients, our study shows that
the choice of ARV was driven by presence of co-morbidities as well as prevention of long-term
toxicities without impairing virologic suppression. Polymedication is a major issue in the geri-
atric and elderly populations, with the risk of increased adverse drug events, drug-drug inter-
actions, inappropriate medications and poor adherence [31]. In a recent study, Greene et al.
show that HIV subjects older than 60 were at high risk of polypharmacy and medications
related problems and that the overall burden of medications has shifted from antiretrovirals to
comorbidities-associated medications and points out the need for a geriatric-sensitive care of
the ageing HIV population [32]. The multidisciplinary approach that is recommended for
ART management including physicians, virologists and pharmacists to optimize HIV infection
management should integrate geriatricians for the patients that enter elderly age [33, 34].
Our study has some limitations; some comorbidities may have been underestimated
because of a non declaration in the patient’s medical chart. However results of a recent French
study evaluating comorbidities in HIV patients over 60 years find similar prevalence of the
major comorbidities (cardiovascular diseases 30%, hypertension 27% and diabetes 15%) [35].
Furthermore individuals who died before Dec 31, 2015 were not included in the study and this
does not allow to evaluate the frequency and reasons of death in this aging population.
In summary, our study points out that a geriatric HIV population is emerging and high-
lights the burden and challenge of this geriatric HIV population who despite more co-morbidi-
ties and more advanced HIV infection achieve similar high rate of virologic suppression than
the elderly population. A systematic multidisciplinary approach, involving general practition-
ers, infectiologists, geriatricians, pharmacists should be developed to face the incoming chal-
lenge of HIV-infected population advancing to geriatric age.
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